Print
Email
Print Edition StoriesFriday, April 4, 2008
FDA OKs Thermo Fisher test for superbug infection
Thermo Fisher Scientific Inc., a provider of research products and services, has won U.S. market clearance for its test to screen patients for a deadly bacteria called MRSA.
MRSA, or methicillin-resistant Staphylococcus aureus, has been a major health concern because of its rising prevalence in Americans and resistance to common antibiotics. Some estimates show MRSA, also called "superbug," causes up to 119,000 deaths in U.S. hospitals per year, according to Thermo Fisher (NYSE: TMO).
The Waltham-based company said its "Spectra" test involves use of a medium in which MRSA shows up in dark blue. The test, marketed by the firm's Remel unit based in Lenexa, Kan., is designed to yield results within a day.
Thermo Fisher, which employs 33,000 workers worldwide, reported 2007 net income of $761.1 million on revenue of $9.7 billion.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
